Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

Introduction: A proof-of-concept study was designed to evaluate the antiviral efficacy, safety and tolerability of a two-drug regimen with dolutegravir 50 mg once daily (QD) plus lamivudine 300 mg once daily as initial highly active antiretroviral therapy (HAART) among antiretroviral (ARV)-naive pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Int AIDS Soc
Autors principals: Cahn, Pedro, Rolón, María José, Figueroa, María Inés, Gun, Ana, Patterson, Patricia, Sued, Omar
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5515053/
https://ncbi.nlm.nih.gov/pubmed/28537061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.20.01.21678
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars